Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Management of acute pain Age: Adult |
Dose: Parenteral intravenous/intramuscular – Initially 40 mg Frequency: followed by 20 or 40 mg every 6-12 hours as required Note: Maximum: 80 mg/day |
|
Indication: Prevention or reduction of post-operative pain Age: Adult |
Dose: Parenteral intravenous/intramuscular – 40 mg Frequency: 30-45 minutes prior to surgical incision Note: May be continued post-operatively as needed for adequate effect |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Severe renal impairment (creatinine clearance less than 30 mL/minute) |
Dose: Lowest recommended dose Note: Severe renal impairment (creatinine clearance less than 30 mL/minute) requires the lowest recommended dose. |
Administration
- Must be reconstituted before use
- For intramuscular or intravenous injection
Side Effect
- Nausea
- pharyngitis
- alveolar osteitis (dry socket)
- anaemia post-op
- hypokalaemia
- agitation
- insomnia
- hypoaesthesia
- dizziness
- HTN
- hypotension
- resp insufficiency
- abdominal pain
- vomiting
- constipation
- dyspepsia
- flatulence
- pruritus
- hyperhidrosis
- back pain
- oliguria
- peripheral oedema
- MI
- Deep vein thrombosis (DVT)
- pulmonary embolism
- stroke
- deep surgical infections
- sternal wound complications
- renal impairment
- increased blood creatinine
- Anaphylaxis
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP3A4 & 2C9 inhibitors
|
Increased AUC
|
|
Oral Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban) including warfarin/coumarin-type & novel oral Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban) (e.g. apixaban, dabigatran & rivaroxaban)
|
Increased risk of bleeding
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
History of CVA, MI, CABG, Uncontrolled HTN, CHF (NYHA II-IV)
|
Increased risk of cardiovascular events
|
|
Active Peptic Ulceration or GI Bleeding
|
Risk of gastrointestinal complications
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.